NCT05674643 Gastric Assessment of Pediatric Patients Undergoing Surgery
| NCT ID | NCT05674643 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Fasting |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2023-02-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot prospective cohort study is to examine the reproducibility of gastric volume and emptying as measured by gastric ultrasound and its correlation to a gold-standard test for gastric emptying in the perioperative period in pediatric patients. The main questions it aims to answer are: * What is the reliability (inter-rater variability between expert and novice assessors, and intra-rater variability) of a) the gastric antral cross-sectional area (CSA) and b) gastric volume using the Perlas US qualitative grading assessment, measured by using an ultrasound device in pediatric patients undergoing general anesthesia for elective surgery? * What is the correlation between ultrasound assessment of gastric emptying by the antral-CSA and gastric emptying determined by the acetaminophen absorption test (AAT), the gold standard? The study will include two cohorts. Cohort assignment will be based on age and anesthesia induction plan. Subjects \>7yrs of age and expected to get an IV induction will be assigned to Cohort #1. Subjects \<7yrs of age and not expected to get an IV induction will be assigned to Cohort #2. * Cohort 1 will include abdominal ultrasound for gastric assessment AND the acetaminophen absorption test which includes administering enteral acetaminophen (tylenol) with 6 oz of water and drawing of blood samples through a peripheral intravenous line. * Cohort 2 will include subjects for whom a peripheral intravenous line placement is not part of routine pre-operative care. Procedures for Cohort 2 will include abdominal ultrasound only in the pre-op area (no tylenol). This cohort is included to examine the reliability of measurements across age groups.
Eligibility Criteria
Inclusion Criteria: * Perioperative patients with ASA classification 1-2 * Ages: 2 years- less than 18 years * Locations: Longwood and Waltham campuses of Boston Childrens Hospital Exclusion Criteria: * History of gastrointestinal surgery * Gastrostomy * Known GI dysmotility (cohort 1 only) * Acetaminophen allergy (cohort 1 only) * Liver or renal dysfunction- pre-diagnosed or, if available, when serum biomarkers are 2 standard deviations above the highest value considered normal for age. (cohort 1 only) * Consumption of acetaminophen in the 4 hours prior (cohort 1 only)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05674643 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying Fasting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05674643 currently recruiting?
Yes, NCT05674643 is actively recruiting participants. Contact the research team at jocelyn.booth@childrens.harvard.edu for enrollment information.
Where is the NCT05674643 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05674643 clinical trial?
NCT05674643 is sponsored by Boston Children's Hospital. The trial plans to enroll 60 participants.